Shattuck Labs, Inc. (STTK) — SEC Filings
Shattuck Labs, Inc. (STTK) — 33 SEC filings. Latest: ARS (Apr 8, 2026). Includes 9 8-K, 6 SC 13G/A, 4 10-Q.
View Shattuck Labs, Inc. on SEC EDGAR
Overview
Shattuck Labs, Inc. (STTK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 8, 2026: Shattuck Labs, Inc. filed an Annual Report to Security Holders (ARS) on April 8, 2026, for the period ending December 31, 2025. The company, located at 500 W. 5th Street, Austin, TX, is involved in Pharmaceutical Preparations. The filing details are associated with SEC Accession No. 0001193125-26-14
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 2 bullish, 30 neutral, 1 mixed. The dominant filing sentiment for Shattuck Labs, Inc. is neutral.
Filing Type Overview
Shattuck Labs, Inc. (STTK) has filed 1 ARS, 1 DEFA14A, 4 10-Q, 9 8-K, 2 DEF 14A, 2 10-K/A, 2 10-K, 1 SC 13D/A, 6 SC 13G/A, 4 SC 13G, 1 8-K/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of STTK's 22 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,000,000 |
| Net Income | -$10,056,000 |
| EPS | -$0.14 |
| Debt-to-Equity | 0.08 |
| Cash Position | $42,548,000 |
| Operating Margin | -1102.6% |
| Total Assets | $100,333,000 |
| Total Debt | $7,093,000 |
Key Executives
- Jeremy C. Green
- Jennifer Ciresi
- Dr. Michael J. Yauch
- Dr. Terry D. H. Huang
- Dr. Michael L. R. Alston
- Dr. Josiah P. Lee
- Abigail P. Johnson
Industry Context
Shattuck Labs operates in the highly competitive biotechnology sector, characterized by long development cycles, significant R&D investment, and regulatory hurdles. Success hinges on the ability to advance drug candidates through clinical trials and secure partnerships or approvals. The industry faces constant pressure to innovate while managing substantial financial risks associated with drug development.
Top Tags
pharmaceuticals (6) · annual-report (4) · corporate-governance (4) · amendment (4) · sec-filing (3) · 10-Q (3) · institutional-ownership (3) · executive-changes (2) · 8-K (2) · material-agreement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| ARS Document Size | 8432288 | Size of the primary ARS PDF document. |
| Complete Submission Text File Size | 11615613 | Size of the full submission text file. |
| Net Loss (Q3 2025) | $10.056M | Decreased from $16.675M in Q3 2024 |
| Net Loss (YTD Sep 2025) | $36.216M | Decreased from $56.731M in YTD Sep 2024 |
| License and Collaboration Revenue (Q3 2025) | $1.000M | Decreased from $2.997M in Q3 2024 |
| Research and Development Expenses (Q3 2025) | $7.618M | Decreased from $16.313M in Q3 2024 |
| Research and Development Expenses (YTD Sep 2025) | $26.218M | Decreased from $51.816M in YTD Sep 2024 |
| Accumulated Deficit | $417.9M | As of September 30, 2025, indicating significant historical losses |
| Cash and Short-Term Investments | $86.1M | As of September 30, 2025, believed sufficient for next twelve months |
| Shares Outstanding | 63,279,843 | As of October 23, 2025 |
| Annual Meeting Date | 20250710 | Shareholders will vote on proposals at this date. |
| Filing Date | 20250521 | Date the proxy statement was submitted to the SEC. |
| Commission File Number | 001-39593 | Identifies the company's filings with the SEC |
| Standard Industrial Classification | 2834 | Industry code for Pharmaceutical Preparations |
| SEC File Number | 001-39593 | Identifies the company's filings with the SEC. |
Forward-Looking Statements
- {"claim":"FMR LLC will likely maintain a significant ownership stake in Shattuck Labs, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Frequently Asked Questions
What are the latest SEC filings for Shattuck Labs, Inc. (STTK)?
Shattuck Labs, Inc. has 33 recent SEC filings from Jan 2024 to Apr 2026, including 9 8-K, 6 SC 13G/A, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of STTK filings?
Across 33 filings, the sentiment breakdown is: 2 bullish, 30 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Shattuck Labs, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Shattuck Labs, Inc. (STTK) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Shattuck Labs, Inc.?
Key financial highlights from Shattuck Labs, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for STTK?
The investment thesis for STTK includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Shattuck Labs, Inc.?
Key executives identified across Shattuck Labs, Inc.'s filings include Jeremy C. Green, Jennifer Ciresi, Dr. Michael J. Yauch, Dr. Terry D. H. Huang, Dr. Michael L. R. Alston and 2 others.
What are the main risk factors for Shattuck Labs, Inc. stock?
Of STTK's 22 assessed filings, 1 were flagged high-risk, 8 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Shattuck Labs, Inc.?
Recent forward-looking statements from Shattuck Labs, Inc. include guidance on {"claim":"FMR LLC will likely maintain a significant ownership stake in Shattuck Labs, Inc. for the foreseeable future.".